Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?Zacks Investment Research • Wednesday
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026GlobeNewsWire • Monday
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026GlobeNewsWire • 10/21/26
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS LawBusiness Wire • 10/11/26
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)PRNewsWire • 09/25/26
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus ErythematosusGlobeNewsWire • 09/23/26
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026GlobeNewsWire • 08/06/26
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/19/26
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study DataZacks Investment Research • 05/21/26